Skip to main content
Signal8

Zivo Bioscience, Inc. (ZIVO)

ZIVO Bioscience, Inc. is a research and development firm that specializes in the creation and commercialization of natural bioactive compounds. These unique ingredients, derived from its proprietary algae cultures, are licensed and sold to manufacturers producing goods for animal health, human consumption, dietary supplements, and medical foods. The company operates at the intersection of biotechnology and agricultural technology, boasting a comprehensive intellectual property portfolio. This includes distinct algal and bacterial strains, advanced biologically active molecules and complexes, innovative production and cultivation techniques, and various inventions, some patented and others pending approval, all geared towards improving human and animal well-being. Its product applications are broad, addressing areas such as promoting gut health in poultry, combating bovine mastitis, improving joint function in canines, modulating the human immune system, providing algal biomass for direct human consumption, and offering biomass-based solutions for skin care and anti-aging. Founded originally as Health Enhancement Products, Inc., the company officially rebranded to ZIVO Bioscience, Inc. in October 2014. Its corporate operations are based in Bloomfield Hills, Michigan.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

ZIVO Bioscience, Inc. logo

ZIVO Bioscience, Inc.

OTC:ZIVOHealthcare
+1.63%$6.25
Mkt Cap$24.3M
Float90K
O/S3.89M
Inst Own0.1%
SI8.7%
Dilution
Historical Data
DateOpenHighLowCloseVolume
Key Metrics
Market Cap$24.30M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership0.11%

based on 3.89M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeOTC
CountryUSUS
IPO DateDec 15, 2003
Shares Outstanding3.89M
Float90,147
Company Overview

ZIVO Bioscience, Inc. is a research and development firm that specializes in the creation and commercialization of natural bioactive compounds. These unique ingredients, derived from its proprietary algae cultures, are licensed and sold to manufacturers producing goods for animal health, human consumption, dietary supplements, and medical foods.

The company operates at the intersection of biotechnology and agricultural technology, boasting a comprehensive intellectual property portfolio. This includes distinct algal and bacterial strains, advanced biologically active molecules and complexes, innovative production and cultivation techniques, and various inventions, some patented and others pending approval, all geared towards improving human and animal well-being.

Its product applications are broad, addressing areas such as promoting gut health in poultry, combating bovine mastitis, improving joint function in canines, modulating the human immune system, providing algal biomass for direct human consumption, and offering biomass-based solutions for skin care and anti-aging. Founded originally as Health Enhancement Products, Inc., the company officially rebranded to ZIVO Bioscience, Inc. in October 2014.

Its corporate operations are based in Bloomfield Hills, Michigan.

Leadership

Alison A. Cornell

Director

Christopher D. Maggiore

Director

John B. Payne

President and Chief Executive Officer / Chairman / Director

Keith R. Marchiando

Chief Financial Officer

Employees

7

Country

US

Sector

Healthcare

Website

zivobioscience.com

Analyst Coverage
Analyst Coverage
ConsensusHold
Price Target
No price targets available
Ratings Distribution
BUY
0
HOLD
1
SELL
0
TOTAL1
Insider Trades
InsiderTypeShares
STROME MARK E profile photoSTROME MARK EPurchase100.0K
YALDOO LAITH L profile photoYALDOO LAITH LPurchase1.5K
STROME MARK E profile photoSTROME MARK EPurchase2.0K
STROME MARK E profile photoSTROME MARK EPurchase20.0K
YALDOO LAITH L profile photoYALDOO LAITH LPurchase2.4K
Cornell Alison A profile photoCornell Alison APurchase11.7K
Shareholders
0.1%
Institutional
(1)
17.3%
Insiderⓘ
(2)
60.5%
5%+ Owners
(6)
of which 48.3% rests on schedules older than 24 months (5 holders)
22.1%
Unattributed (incl. retail)ⓘ
Institutional0.1%
Insider17.3%
5%+ Beneficial60.5%
Unattributed (incl. retail)22.1%
Top Shareholders
NameShares%
YALDOO LAITH L profile photo
YALDOO LAITH L
Director, 10% Owner
542.1K13.9%
HEP Investments LLC 45-3135062 logo
HEP Investments LLC 45-3135062
· may incl. warrants· stale · filed Oct 2024
531.0K13.7%
Mark E. Strome logo
Mark E. Strome
· may incl. warrants· filed Feb 2026
472.9K12.2%
Christopher D. Maggiore logo
Christopher D. Maggiore
· may incl. warrants· stale · filed Jun 2024
458.4K11.8%
Keith Marchiando logo
Keith Marchiando
· may incl. warrants· stale · filed Jun 2024
341.6K8.8%
John Bernard Payne logo
John Bernard Payne
· may incl. warrants· stale · filed Jun 2024
305.9K7.9%
Alison A. Cornell logo
Alison A. Cornell
· may incl. warrants· stale · filed Jun 2024
242.2K6.2%
Masterson Nola E profile photo
Masterson Nola E
Director
130.9K3.4%
CoreCap Advisors, LLC logo
CoreCap Advisors, LLC
4.4K0.1%
Sources: 13F, Form 4, 13D/13GO/S: 3.9M · as of 9 Nov 2025 · SEC cover page
Insiders & Institutional Holders

Top institutional holders

52-Week Range
$1.10$17.50
$6.25(31st percentile)
Volume
Average Daily Volume1.37K
153 today vs 1.37K avg(-89%)

30d Avg

1.37K

60d Avg

1.15K

90d Avg

1.04K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...